Variations in eosinophil chemokine responses: an investigation of @entity16951 and @entity23427 function, expression in @entity402 , and identification of a functional XXXX promoter.

@entity23427 @entity66 @entity16951 @entity402 @entity14700 @entity56 @entity9536 @entity10557
We previously showed in a small group of donors that eosinophils from a subgroup of individuals responded equipotently to CC chemokine ligand ( @entity14700 /eotaxin and @entity10557 / @entity10557 in assays of eosinophil shape change ( @entity10557 / @entity10557 -highly responsive (MHR) donors). In this study, we investigated the functional role of @entity10557 in eosinophil responses in 73 donors. MHR donors, identified by their eosinophil shape change responses, represented approximately 19% of the donor pool. Eosinophils from these donors showed increased eosinophil @entity16951 expression and also underwent @entity10557 -mediated chemotaxis and up-regulation of @entity9536 . All MHR donors gave a history of @entity66 . In a further study, we prospectively recruited 110 subjects, subdivided into nonatopics or atopics, and investigated expression of @entity16951 and @entity23427 on eosinophils, basophils, monocytes, and neutrophils. Eosinophil @entity16951 expression was non-normally distributed in atopics, although higher @entity16951 expression levels were not predictive of a diagnosis of @entity402 or @entity66 . We identified the @entity16951 promoter and investigated its function. We found a minimal promoter within 177 bp of the transcription start site, and an upstream enhancer region that facilitated expression in leukocyte cell lines. Collectively, these data demonstrate that MHR individuals form an important subgroup that, when associated with a diagnosis of @entity56 , may require tailored therapy to modulate eosinophil recruitment. Identification of a functional @entity16951 promoter will facilitate the study of possible genetic determinants underlying this potentially important clinical phenotype.
